Editorial: End Brand-Name Rx Makers’ Control of Market

The practice of allowing brand-name prescription drugmakers to pay makers of generic drugs to delay market entry of generic products should be stopped, a Washington Post editorial states. The editorial supports legislation before the U.S. Senate Appropriations Committee that would ban such practice for competitive reasons, concluding that consumers could wind up saving billions of dollars.

• "Ending 'Pay for Delay' Tactics on Generic Drugs Could Mean Lower Prices" (Washington Post, 7/29).